Locations:
December 10, 2017/Cancer/Research

Predictors of 30-day Unplanned Readmissions in Patients with Hematologic Malignancies

Disease-related, clinical and discharge-associated factors

mukherjee_650x450

Patients with hematologic malignancies (HM) are at risk of recurrent 30-day unplanned readmissions (UR), given high symptom burdens and repeated courses of chemotherapy. A team of Cleveland Clinic researchers, led by Sudipto Mukherjee, MD, PhD, MPH, recently sought to identify predictors of recurrent 30-day UR in patients with HM as a first step toward designing interventions for this group. Girish Kunapareddy, MD, MBA, a fellow at Cleveland Clinic Cancer Center, was first author on the abstract.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

The study included 259 30-day UR involving 157 hematologic malignancy patients treated at Cleveland Clinic between 2012 and 2015. Hematologic malignancies included in the analysis were acute leukemias, myelodysplastic syndromes and aggressive lymphomas. The tables below show disease-related, clinical and discharge-associated factors that are associated with 30-day UR and independently predictive of subsequent 30-day UR.

”We found several predictors of recurrent 30-day UR, notably gastrointestinal symptoms, prior admission for febrile neutropenia, those with relapsed refractory disease and constitutional symptoms, among others,” says Dr. Mukherjee, associate staff in the Department of Hematology and Medical Oncology at Cleveland Clinic Cancer Center. “These data shed light on potential areas that can be targeted for interventions to reduce these UR, which are a significant burden on these patients and not an optimal use of medical resources.” For instance, the subset of patients with relapsed/refractory disease may particularly benefit from a specialized program that includes individualized symptom management from a coordinated team and closer ambulatory follow-ups. As part of efforts to reduce 30-day UR, Cleveland Clinic has instituted five-day follow-up for all cancer patients discharged after hospitalization.

Photo Credit: ©Russell Lee

Advertisement

Related Articles

Dr. Arun Singh
October 21, 2026/Cancer

Preserving Vision in Uveal Melanoma (Podcast)

Understanding expanding treatment options and potential advances

Patient and doctor
October 9, 2026/Cancer/News & Insight

First Radioligand Therapy Approved for Metastatic Hormone-Sensitive Prostate Cancer

Adding 177Lu-PSMA-617 to ADT plus an ARPI cut the risk of radiographic progression or mortality by 28%

Woman running
October 7, 2026/Cancer/Patient Support

Pilot Project Aids Cancer Survivors in Achieving Healthy Weight and Reducing Recurrent Risk

New program will help patients improve fitness and manage weight after cancer treatment

Dr Keith McCrae
October 6, 2026/Cancer/Benign Hematology

How is ITP Therapy Evolving?

Cleveland Clinic hematologist highlights new guidelines and treatment advances in immune thrombocytopenia

Bone metastasis
October 5, 2026/Cancer/Innovations

Digital Platform Cuts Bone Metastasis Treatment Decision Time

NIMBLE replaces weekly tumor board delays with same-day multidisciplinary recommendations

Prostate cancer
October 2, 2026/Cancer/Radiation Oncology

ArteraAI Prostate Biomarker Accurate Across Diverse Populations

Cleveland Clinic study provides validation for the test, which combines AI and pathological data to predict outcomes in postoperative patients

Prostate cancer illustration
October 1, 2026/Cancer/Radiation Oncology

PSMA PET Scan-Guided LDR Brachytherapy Can Control Localized Prostate Cancer Recurrence

Advanced imaging technology catches metastases much earlier, allowing treatment with fewer side effects

Throat cancer
September 30, 2026/Cancer/Radiation Oncology

Same Cure Rate, Less Radiation in HPV-Associated Oral Cancer

Reduced radiation for lymph node areas reduces side effects

Ad